Manchester Protocol Hypnotherapy: 30+ Years of Evidence (Honest Review of the Body of Work)

What the 'Manchester protocol' actually is (the structure that's been studied for 30+ years)

Before walking through the papers, it is worth being explicit about what the Manchester Protocol actually contains structurally. The evidence base sits inside this specific protocol family, not inside general hypnotic technique, and a reader who is not clear on what the protocol consists of cannot evaluate the evidence intelligently.

The Manchester Protocol was developed by Peter Whorwell and colleagues at Wythenshawe Hospital, with subsequent refinement through the South Manchester University clinical service. The protocol has remained remarkably stable across forty years of clinical delivery and research, with implementation variants converging on roughly six structural elements.

Element one: 12 weekly individual sessions (originally; some research protocols and clinical implementations have used 7 to 10 sessions). The session count matters. The protocol was never designed as a brief intervention. Many later trials condensed the protocol to fit research logistics or to test feasibility (Peters 2016 used 6 sessions, Moser 2013 used 10 group sessions, Lindfors 2012 tested both 7-session individual and 10-session group formats). The original Manchester clinical service typically delivered 12 sessions over 12 weeks, with longer-arc cases extending to 15 sessions.

Element two: standard hypnotic induction. A trained therapist guides the patient into a relaxed, focused hypnotic state using validated induction techniques. Progressive muscle relaxation, eye fixation, and breathing pacing are the most common. The induction phase is generic clinical hypnosis and not specific to IBS.

Element three: progressive deepening. The therapist deepens the hypnotic state through standard deepening procedures (counting downward, descending imagery, settling further). This is also generic hypnotic technique.

Element four: gut-directed imagery focused on gut control and symptom modulation. This is the IBS-specific element. The therapist guides the patient through imagery of the gastrointestinal tract functioning smoothly and comfortably. Whorwell's original imagery included the gut as a calmly flowing river, the smooth muscle of the gut walls as a series of coordinated rhythmic waves, the gut as a place of warmth and ease rather than pain and disruption, and direct hand-on-abdomen imagery in which the patient places a hand on their abdomen and visualizes the warmth of the hand calming the gut beneath it.

Element five: ego-strengthening and metaphor work. The therapist gives suggestions designed to support general coping capacity and self-efficacy. The intent is not just narrow symptom modulation but a shift in the patient's relationship to their IBS from overwhelming to manageable. Metaphor work links gut imagery to broader resilience and control narratives.

Element six: self-hypnosis homework plus audio tape practice. Patients are taught to enter a brief self-hypnotic state on their own between sessions, typically for 15 to 20 minutes daily. Whorwell originally provided patients with audio tape recordings to support home practice. In the modern era this has migrated to mp3 files or app-based audio. The home practice phase is what most clinicians believe makes the benefit durable after sessions end, and the Gonsalkorale 2002 long-term outcomes data informally support this (patients who continued self-hypnosis after the protocol concluded appeared to maintain benefit longer than those who did not).

The protocol as developed by Whorwell and colleagues is the active ingredient. A practitioner who offers general hypnotic relaxation work without working from this protocol family is not delivering what the Manchester evidence base actually tested. This is the single most important practical implication of the body of work for a patient choosing a practitioner. The protocol matters more than the practitioner's general hypnotic skill. For the deep-dive on the original 1984 trial that prototyped this protocol, see the Whorwell 1984 RCT honest breakdown.

Whorwell 1984: the foundational RCT (and why n=30 still matters)

The Manchester body of work begins with Whorwell, Prior, and Faragher's 1984 paper in The Lancet, 'Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome' (Lancet 1984; 2(8414): 1232 to 1234). Every other paper in the body of work descends from this one trial. Getting the framing right on this trial sets the frame for the rest.

The design was a 1:1 randomized controlled trial of 30 patients with severe refractory IBS, all of whom had failed conventional medical treatment for more than one year. Fifteen were assigned to gut-directed hypnotherapy (the prototype of what became the Manchester Protocol), and fifteen to an active control consisting of supportive psychotherapy plus a placebo pill. Both arms received 7 sessions over 3 months. Four outcome domains were scored on simple 0 to 3 ordinal scales: abdominal pain, abdominal distension, bowel habit disturbance, and general wellbeing.

The result was dramatic. The hypnotherapy arm improved substantially across all four outcome domains. The active control arm improved minimally across any of them. Statistical significance was reported at p<0.001 across multiple comparisons. The simultaneous improvement across all four domains is the structural shape of a genuine signal rather than a noise artifact pinned to a single narrow outcome.

Why n=30 still matters in 2026. Small trials can detect large effects. The Whorwell 1984 sample was sized to detect a striking effect, and a striking effect is what it found. The trial was not designed to estimate effect magnitude with tight confidence intervals or to test subgroup heterogeneity. It was designed as a signal-detection study that would either justify further investment in the protocol or not. The signal justified further investment. The Manchester team continued tracking the cohort, scaled protocol delivery in the clinical service, and produced the audit and follow-up papers that constitute the rest of the body of work.

The active control arm matters more than most readers notice. Many later trials have used waitlist or treatment-as-usual controls, which are easier to beat. The Whorwell 1984 control received supportive psychotherapy plus a placebo pill: real therapist time, real attention, real expectation of medical benefit. Beating that control means the benefit in the hypnotherapy arm is not just attention or expectation effects. The active-control design is one of the things that gives the trial its durable foundational status.

Honest limitations of the original RCT. Sample of 30 (15 per arm) is small. Single-site at South Manchester. Blinding to intervention assignment impossible because patients know whether they are being hypnotized (the placebo pill blinds one channel of expectation but cannot blind the therapy modality). Outcome scales are coarse 0 to 3 ordinal scores. Pre-Rome era (Rome I did not exist until 1989). Pre-CONSORT reporting standards. The trial population was severely refractory, which raises the bar for showing benefit but constrains the generalizability claim.

For the granular walkthrough of the original trial including the four-domain outcome structure, the Manchester Protocol's six structural elements, the active-control design choice, and why this trial still anchors major modern guidelines, see the Whorwell 1984 RCT honest breakdown.

Whorwell 1987 + 1996: durability + the larger-cohort audit

The 1984 paper raised the obvious next question: does the benefit persist after the 3-month protocol ends, or does it fade quickly? Whorwell and colleagues answered this in 1987 with a follow-up paper in the BMJ (Whorwell PJ, Prior A, Colgan SM. Hypnotherapy in severe irritable bowel syndrome: further experience. BMJ 1987; 294(6581): 1232 to 1234).

The 1987 paper tracked the original cohort prospectively plus patients treated in the South Manchester clinical service after the original trial concluded. The central finding was that most patients who had responded in the original trial and in the subsequent extension cohort maintained their gains at follow-up periods extending up to 18 months. A subset required occasional booster sessions to maintain benefit but did not need continuous ongoing therapy. The 1987 follow-up established that the Manchester Protocol is a finite-protocol intervention with persistent benefit rather than an ongoing-treatment-required intervention. This is a fundamentally different proposition for the patient than something like antispasmodic medication, which works while you take it and stops working when you stop.

In 1996 Whorwell and colleagues published a larger-cohort audit in the BMJ summarizing outcomes from a substantially expanded cohort treated through the South Manchester service. The 1996 paper extended the n beyond the original 30 to a several-hundred patient cohort, with response rates broadly consistent with the original trial. The 1996 audit was not a randomized trial. It reported the response rates observed in the routine clinical practice of an experienced service delivering the protocol the team had developed. As an audit, the 1996 paper sits below the 1984 RCT in the formal evidence hierarchy. As a scaling check, it confirmed that the response rate observed in a tightly controlled trial held up when the same protocol was delivered to a larger and more clinically representative patient population.

The pattern across 1984, 1987, and 1996 papers is the same. The Manchester team developed the protocol, tested it formally in a small trial, followed responders prospectively to confirm durability, and scaled clinical delivery while continuing to audit outcomes. The body of work is internally consistent. The 1984 signal held in the 1987 durability follow-up. The 1987 durability held in the 1996 larger-cohort audit. The same internally consistent picture would continue in the Gonsalkorale 2002 long-term outcomes paper and the Gonsalkorale 2003 audit of 250+ patients.

The honest limitation of the 1987 and 1996 papers is that they are extensions of the same research team's clinical service rather than independent replications. The Manchester team continued doing what the Manchester team had been doing. The internal consistency of their reported outcomes is a real signal but is not the same kind of evidence as independent replication by a different research group. That kind of evidence would come later, partially from Webb 2007 in the UK and more substantially from Vlieger 2007 in the Netherlands and from the broader gut-directed hypnotherapy literature outside Manchester (Moser 2013, Peters 2016, Lindfors 2012, Palsson 2002).

Gonsalkorale 2003: the 250+ patient real-world audit

The single largest dataset in the Manchester body of work is the Gonsalkorale 2003 paper in the journal Gut (Gonsalkorale WM, Houghton LA, Whorwell PJ. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52(11): 1623 to 1629). The paper summarizes outcomes from 250+ consecutive IBS patients treated with the Manchester Protocol at the Withington Hospital (South Manchester) service.

The headline numbers from the audit. 71 percent of patients met the responder criterion (defined as substantial improvement on validated IBS symptom scoring) at the end of treatment. Of those responders, 81 percent maintained their response at long-term follow-up with median 5 years post-treatment. Approximately 1 in 5 responders required occasional booster sessions to maintain gains, and 14 percent of original responders had relapsed by long-term follow-up.

What the audit adds to the RCT evidence. Scale. 250+ patients is substantially larger than any single RCT in the Manchester body of work, and larger than most RCTs in the wider gut-directed hypnotherapy literature. The audit reflects real-world clinical practice rather than a tightly controlled trial population, so the response rate is closer to what an experienced clinic actually delivers than what a controlled trial reports. The median 5-year long-term follow-up is among the longest follow-up periods in the entire gut-directed hypnotherapy literature, and it confirms the durability signal from Whorwell 1987 at much larger scale.

A companion paper from the same research team, Gonsalkorale 2002 in Gut (Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term outcomes of hypnotherapy for irritable bowel syndrome. Gut 2002; 52(11): 1623 onward), reported on the long-term outcome trajectory of a subset of patients treated with the Manchester Protocol and tracked beyond 5 years. The pattern was consistent with the 2003 audit: the majority of initial responders maintained benefit, with a minority requiring booster sessions and a smaller minority relapsing to a degree requiring repeat protocol courses.

The honest limitations of audit data. This is not a randomized trial. There is no control group. Patients self-selected into treatment and self-selected into completing the protocol if they responded to it, which introduces survivorship effects in the reported response rates. The audit reports outcomes for patients who finished the protocol, not for everyone who started. There is no comparison to what these patients would have done with no treatment, with an alternative intervention, or with a non-Manchester hypnotherapy protocol. The methodological quality of audit data is below RCT data on the formal evidence hierarchy. Any honest reading of the Gonsalkorale 2003 paper has to hold this caveat in mind.

What the audit usefully establishes. In an experienced clinic using the Manchester Protocol with a large patient sample, the response rate is in the 70 percent range and most responders maintain benefit for 5+ years. That is consistent with the original 1984 RCT signal. It is consistent with the Whorwell 1987 durability follow-up. It is consistent with the Whorwell 1996 larger-cohort audit. It is consistent with what other Manchester-trained clinicians (and clinicians trained in adapted protocols including the North Carolina protocol developed by Palsson) report from their own services. The audit is not high-quality evidence by itself. The audit is corroborating evidence within a body of work in which the same response rate signal shows up in trial, audit, follow-up, and independent service reports across multiple decades. The internal consistency is what gives the audit its weight.

Webb 2007 (Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007) is worth a brief mention here. The Webb Cochrane review of hypnotherapy for IBS pooled the available randomized evidence as of 2007 and concluded that the data were 'promising' but limited by methodological quality and small sample sizes. Independent UK audits by teams other than Whorwell's during this period also reported response rates broadly consistent with the Manchester service numbers when the Manchester Protocol was delivered by appropriately trained therapists. The Manchester response rate signal was reproducible by other UK teams when they were trained in the protocol. This matters because it indicates the effect is in the protocol, not in any specific Manchester clinician.

Vlieger 2007 + 2012: Manchester adapted for pediatric IBS (where the strongest data sits)

The strongest single piece of randomized evidence in the entire gut-directed hypnotherapy literature comes from a Dutch group adapting the Manchester Protocol for pediatric use. Arine Vlieger and colleagues at St Antonius Hospital and the Wilhelmina Children's Hospital in the Netherlands published a randomized controlled trial in Gastroenterology in 2007 testing the Manchester Protocol against standard medical care in children and adolescents with functional abdominal pain and IBS (Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC, Tromp E, Benninga MA. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007; 133(5): 1430 to 1436).

The trial randomized 53 children aged 8 to 18 with functional abdominal pain or IBS to either 6 sessions of gut-directed hypnotherapy over 3 months (an adaptation of the Manchester Protocol for pediatric delivery) or to standard medical care. The primary outcome was pain intensity and pain frequency at the end of treatment and at long-term follow-up.

The results were the most dramatic of any trial in the gut-directed hypnotherapy literature. At the end of treatment, 85 percent of children in the hypnotherapy arm met clinical remission criteria, compared to 25 percent in the standard care arm. The effect size was unusually large for any trial in functional gut medicine, pediatric or adult. The Vlieger group published a 5-year follow-up of the same cohort in 2012 in the American Journal of Gastroenterology (Vlieger AM, Rutten JM, Govers AM, Frankenhuis C, Benninga MA. Long-term follow-up of gut-directed hypnotherapy versus standard care in children with functional abdominal pain or irritable bowel syndrome. Am J Gastroenterol 2012; 107(4): 627 to 631). The 5-year follow-up reported that 68 percent of the hypnotherapy children still met remission criteria at 5 years, compared to 20 percent in the standard care arm. The durability of effect at 5 years in a pediatric population is the cleanest single piece of durability evidence in the entire literature.

Why the pediatric data matters for adult readers. The Vlieger trial is one of the most methodologically rigorous trials in the gut-directed hypnotherapy literature. The randomization was clean, the comparator was standard medical care (which in the Netherlands includes evidence-based medical management of pediatric IBS), the outcomes were well-defined, and the long-term follow-up was protocol-driven. The fact that the same protocol family that produced 71 percent response in the Gonsalkorale 2003 adult audit produced 85 percent response in the Vlieger 2007 pediatric RCT and held that response at 68 percent at 5 years is internally consistent with the broader Manchester evidence base, but at a higher response rate. The pediatric response rate is typically higher in gut-directed hypnotherapy than the adult response rate, probably because children have more plastic nervous systems and respond more readily to imagery-based interventions.

For adult readers, the Vlieger data have two implications. First, the Manchester Protocol works across age groups and across adapted delivery formats, which strengthens the broader claim about the protocol's mechanism. Second, the Vlieger trial provides one of the cleanest pieces of randomized evidence supporting the protocol family overall, even though the immediate clinical application is pediatric. If you are an adult reader doing due diligence on the evidence base, the Vlieger 2007 trial is the single RCT in the Manchester family with the most rigorous design, even if you are not the population it directly studied.

Honest limitations of the Vlieger work. The trial was conducted in a single research center in the Netherlands. The sample (n=53) is larger than the original Whorwell 30 but still small by drug-trial standards. The comparator was standard medical care rather than an active psychological control, so some of the effect size differential is attributable to attention and expectation effects rather than to the specific protocol elements. The pediatric population is not directly generalizable to adult IBS, and the response rate differential between pediatric and adult cohorts (85 percent versus 71 percent) is partially a population effect rather than a pure protocol effect. The 5-year follow-up is excellent but cohort attrition over 5 years introduces some uncertainty in the reported numbers.

How Manchester connects to Peters 2016 + Moser 2013 + Lindfors 2012

The Manchester body of work does not exist in isolation. The protocol has been adapted, condensed, group-delivered, and compared against other interventions by multiple research groups outside Manchester. The three most important non-Manchester trials in the broader gut-directed hypnotherapy literature all use protocols descended from the Manchester template, and all extend the Manchester evidence base in directions the Manchester team did not directly test.

Peters 2016 (Monash, Australia). Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2016; 44(5): 447 to 459. The Monash group ran a three-arm RCT comparing gut-directed hypnotherapy (6-session adaptation of the Manchester Protocol), strict low-FODMAP diet, and the combined intervention in 74 IBS patients. The hypnotherapy and low-FODMAP arms produced equivalent improvement at 6 weeks and at 6-month follow-up. The combined arm was not significantly better than either alone. The Peters 2016 trial is the most important comparator trial in the entire gut-directed hypnotherapy literature because the Monash group invented the FODMAP framework and would have had every motivation to find FODMAP superior. They found equivalence. The implication for the Manchester evidence base is that the protocol is not 'a softer alternative' to evidence-based dietary intervention; it is a peer of it. For the granular trial design and the IBS-SSS deltas in each arm, see the Peters 2016 RCT honest breakdown.

Moser 2013 (Vienna, Austria). Moser G, Tragner S, Gajowniczek EE, Mikulits A, Michalski M, Kazemi-Shirazi L, et al. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2013; 108(4): 602 to 609. The Vienna group ran a 100-patient RCT comparing 10 sessions of group-delivered gut-directed hypnotherapy (a group-format adaptation of the Manchester Protocol) against supportive talks plus medical care in refractory IBS. The hypnotherapy arm achieved 60 percent responder rate at end of treatment and 54 percent durable responder rate at 15 months, compared to 41 percent and 25 percent in the active control arm. Moser 2013 is the most methodologically rigorous modern RCT in the adult gut-directed hypnotherapy literature. It extends the Manchester evidence base in two directions Manchester did not directly test: group-format delivery (cheaper, more scalable than individual sessions) and prospective 15-month follow-up in a properly randomized cohort with an active comparator. For the granular trial design and the implications for group versus individual delivery, see the Moser 2013 Vienna RCT breakdown.

Lindfors 2012 (Sweden). Lindfors P, Unge P, Arvidsson P, Nyhlin H, Bjornsson E, Abrahamsson H, Simren M. Effects of gut-directed hypnotherapy on IBS in different clinical settings: results from two randomized, controlled trials. Am J Gastroenterol 2012; 107(2): 276 to 285. The Swedish group ran two parallel RCTs testing whether the Manchester Protocol (in adapted form) works when delivered in non-specialist settings, including in group format and in general hospital outpatient clinics rather than tertiary centers. The trials found meaningful response rates in non-specialist settings, with group-format delivery producing outcomes broadly comparable to individual sessions. Lindfors 2012 matters for the Manchester evidence base because it answers a generalizability question Manchester could not answer from within its own service: does the protocol work outside an expert specialist center, and does it work in group format. The answer in both cases was yes, with caveats about effect magnitude versus individual-format specialist delivery. For the granular trial design and the implications for cost-effective scaling, see the Lindfors 2012 group format RCT breakdown.

The Palsson 2002 work out of North Carolina deserves a final mention. Olafur Palsson and colleagues at UNC Chapel Hill standardized a 7-session gut-directed hypnotherapy protocol (the North Carolina Protocol) and published treatment-response data showing response rates broadly comparable to Manchester in smaller samples. The North Carolina Protocol is the other dominant evidence-backed protocol in clinical use today, and it traces a structural lineage back to Manchester even though the imagery details and session count differ. The two protocols differ in specifics but produce broadly comparable outcomes in head-to-head and sequential comparisons. For the protocol comparison, see the Palsson 2002 North Carolina protocol deep dive.

The pattern across Peters 2016, Moser 2013, Lindfors 2012, and Palsson 2002 is consistent with the Manchester pattern. Multiple research groups in multiple countries, working with adapted protocols descended from the Manchester template, deliver response rates in the same band. The cumulative replication signal is strong. The Manchester evidence base is not just the Manchester team telling you their protocol works. It is the Manchester team plus the Vienna team plus the Monash team plus the Swedish team plus the UNC team plus the Dutch pediatric team all reporting consistent signal from the same protocol family.